Navigating the evolving and complex healthcare data, policy, and regulatory requirements for cell and gene therapies presents new challenges to patient access. Supporting indications across lymphoma, leukemia, hemophilia and more, we have a proven strategy to ensure we remove the barriers patients face when seeking treatment.
.jpg "Landingpage_1 (1)")
Study designs are rapidly transforming. More comprehensive solutions are required to collect critical evidence beyond the walls of the traditional study setting. So how do you plan, prioritize, and educate internal partners as you help your company enter the world of decentralized trials? Dive into UBC's playbook to uncover the key considerations today.
.jpg "section_1_images_3 (1)")
Before the selection of important safety, clinical development and late stage vendors, it’s paramount to understand what is the best match for your company. This webinar will help you understand how consultants can improve the overall experience of working with a CRO and discuss how consultants can help problem solve your companies challenges and the importance of the appropriate vendor selection.
.jpg "pv_vert2 (1)")
UBC was selected by a mid-size pharmaceutical company to provide pharmacovigilance (PV) services of more than 11,000 existing cases for six oncology products. The program resulted in no critical findings during an FDA and Medicines and Healthcare Products Regulatory Agency (MHRA) audit.
.jpg "section_1_images_4 (1)")
Jersino Jean-Mary, Executive Director, European Late Stage Operations, and Aaron Berger, Executive Director, North American Late Stage Operations, shared their thoughts on how the pandemic is impacting clinical trials and post-approval research, and ways that the industry is working together to get patients the access they vitally need to novel therapies.
